Peptide Research Literature Index
A structured, dated index of the research-peptide landscape

Can you be convicted for what an employee did? The Supreme Court said yes in 1975 with no proof you knew anything — and the one defense that exists has to be asked for, which the man the doctrine is named after never did

Reference page · published 2026-10-28

Disclosure: this index is operated by Artemis Labs, which sells research compounds to laboratories. This page is about personal criminal liability for the people who run companies like ours, so our interest in it is direct and it goes at the top rather than the bottom. Nothing here is legal advice. If you are an officer or owner of a company that ships anything regulated as a drug, the only correct use of this page is to take it to a lawyer. Nothing on this page tells anybody how to use any compound. Every quotation below is verbatim from a United States Supreme Court opinion, the United States Code, or the Food and Drug Administration's own internal manual — each document fetched and read for this page on October 28, 2026, and each listed under Sources. One document we fetched for this page cannot be quoted at all, and the section that says so explains why.

Short answer: yes, and FDA has a named, written procedure for it. Under the Federal Food, Drug, and Cosmetic Act, a company officer can be convicted of a misdemeanor for a violation he did not commit, did not order, and did not know about. The government does not have to prove intent. It does not have to prove negligence. FDA says this itself, in a manual it gives its own staff: the doctrine provides that a responsible corporate official can be held liable for a first-time misdemeanor (and possible subsequent felony) under the Act without proof that the corporate official acted with intent or even negligence, and even if such corporate official did not have any actual knowledge of, or participation in, the specific offense. The fine in the case that gave the doctrine its name was $50 per count. That is not the part that matters. The part that matters is that once you have one conviction under this Act, your next violation is a felony.

Start with the statute, and notice the word that is missing

Two short provisions do all the work. The first is the list of things the Act forbids. It opens like this:

The following acts and the causing thereof are prohibited: (a) The introduction or delivery for introduction into interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded.

Read the first six words again — and the causing thereof. The prohibition does not only reach the person who ships the goods. It reaches whoever caused the shipping. That is the hook the entire doctrine hangs on.

The second provision is the penalty, 21 U.S.C. § 333(a). Paragraph (1) is the misdemeanor tier:

Any person who violates a provision of section 331 of this title shall be imprisoned for not more than one year or fined not more than $1,000, or both.

Now look for a word describing a state of mind. There is none. No knowingly, no willfully, no with intent to. The sentence says Any person who violates and stops. Compare paragraph (2), the felony tier, which does mention a state of mind — and also mentions something else:

if any person commits such a violation after a conviction of him under this section has become final, or commits such a violation with the intent to defraud or mislead, such person shall be imprisoned for not more than three years or fined not more than $10,000, or both.

Those are two separate routes to the felony, joined by or. Intent to defraud is one of them. A prior final conviction is the other, and it needs no intent at all. Hold onto that; it is why a $50 fine is not a small thing.

The case: a grocery chain, two warehouses, and a president who delegated

The doctrine is named after United States v. Park, argued in March 1975 and Decided June 9, 1975. John R. Park was the president and chief executive officer of Acme Markets, Inc. The opinion describes the company's size:

approximately 36,000 employees, 874 retail outlets, 12 general warehouses, and four special warehouses

In April 1970, FDA wrote to Park about rodents in Acme's Philadelphia warehouse. In 1971, inspectors found similar conditions in the company's Baltimore warehouse. FDA wrote again in January 1972. That second letter read, in part:

We note with much concern that the old and new warehouse areas used for food storage were actively and extensively inhabited by live rodents.

And it closed with a sentence that will look familiar to anybody who has ever read a modern FDA warning letter:

We trust this letter will serve to direct your attention to the seriousness of the problem and formally advise you of the urgent need to initiate whatever measures are necessary to prevent recurrence and ensure compliance with the law.

Park was charged along with the company. The company pleaded guilty. Park did not. His defense was the one almost every executive would give, and it was true: he ran a company with 36,000 people, he had an organizational structure, and sanitation was somebody else's job. Under cross-examination he agreed that sanitary conditions were something he was responsible for in the entire operation of the company, and that it was one of many things he assigned to dependable subordinates.

The jury convicted him. He was sentenced to pay a fine of $50 on each count. The information had five counts, so by arithmetic that is a total of $250 — the arithmetic is ours; the opinion states the per-count figure. The Court of Appeals threw the conviction out, holding that the government should have had to prove some wrongful act by Park himself. The Supreme Court reversed the Court of Appeals, and the conviction stood.

The test the Court wrote, in one sentence

This is the operative passage. It is quoted here whole, including the clause at the front that cuts in the defendant's favor:

The concept of a 'responsible relationship' to, or a 'responsible share' in, a violation of the Act indeed imports some measure of blameworthiness; but it is equally clear that the Government establishes a prima facie case when it introduces evidence sufficient to warrant a finding by the trier of the facts that the defendant had, by reason of his position in the corporation, responsibility and authority either to prevent in the first instance, or promptly to correct, the violation complained of, and that he failed to do so.

Strip it to its parts and the government must show three things:

Notice what is not on the list. Not knowledge. Not an order he gave. Not a thing he did. The failure to exercise authority is the act.

The Court said so directly, describing the duty the Act imposes:

the Act imposes not only a positive duty to seek out and remedy violations when they occur but also, and primarily, a duty to implement measures that will insure that violations will not occur

Read and primarily. The main duty is not cleaning up problems. It is building a system that stops them happening. Fixing it afterwards is the secondary obligation. And the Court was candid about how heavy that is:

The requirements of foresight and vigilance imposed on responsible corporate agents are beyond question demanding, and perhaps onerous, but they are no more stringent than the public has a right to expect of those who voluntarily assume positions of authority in business enterprises whose services and products affect the health and well-being of the public that supports them.

Where this came from: 1943, and a sentence with a carve-out in it

Park did not invent the idea. It inherited it from United States v. Dotterweich, decided in 1943, which held that an individual at a company — not just the company — could be prosecuted under the Act. The 1943 Court put it this way, and the carve-out in the middle of the sentence is part of the holding, not an aside:

The offense is committed, unless the enterprise which they are serving enjoys the immunity of a guaranty, by all who do have such a responsible share in the furtherance of the transaction which the statute outlaws, namely, to put into the stream of interstate commerce adulterated or misbranded drugs.

That guaranty is a real and separate defense written into the same statute, and we have a standing page on it — it is the mechanism by which a seller who got a written assurance from a supplier can escape the misdemeanor tier. It is worth knowing that Dotterweich built it into the sentence that creates the liability.

The 1943 Court also refused to pretend this was comfortable:

Hardship there doubtless may be under a statute which thus penalizes the transaction though consciousness of wrongdoing be totally wanting.

And it declined to say in advance who was covered, leaving it to each trial: Whether an accused shares responsibility in the business process resulting in unlawful distribution depends on the evidence produced at the trial and its submission to a jury under appropriate guidance. That refusal to draw a line is still the law, and FDA repeats it in its own manual, which we come to below.

In the founding case, the company was not convicted and the officer was

If you want one fact that shows how far this liability runs independently of the company's own guilt, it is the posture of Dotterweich itself. The Park Court described it:

In Dotterweich, a jury had disagreed as to the corporation, a jobber purchasing drugs from manufacturers and shipping them in interstate commerce under its own label, but had convicted Dotterweich, the corporation's president and general manager.

Read that twice. The jury could not agree about the company. It convicted the man who ran it. The case that established that an individual can be reached under this Act is a case in which the corporation was not convicted at all.

So the common assumption — that the company is the primary defendant and officers are an add-on if things get bad enough — is not how the doctrine is built. The individual's liability is not derivative of a corporate conviction. It does not wait for one.

The one defense, and the fact that Park never asked for it

There is a limit, and it is narrow. The Court wrote:

The duty imposed by Congress on responsible corporate agents is, we emphasize, one that requires the highest standard of foresight and vigilance, but the Act, in its criminal aspect, does not require that which is objectively impossible.

So the defense is objective impossibility. Practically, it is raised as a claim that you were powerless:

permits a claim that a defendant was 'powerless' to prevent or correct the violation to 'be raised defensively at a trial on the merits.'

And the burden structure matters, because it is better for a defendant than it first looks:

If such a claim is made, the defendant has the burden of coming forward with evidence, but this does not alter the Government's ultimate burden of proving beyond a reasonable doubt the defendant's guilt, including his power, in light of the duty imposed by the Act, to prevent or correct the prohibited condition.

You must produce evidence. The government still has to prove your power beyond a reasonable doubt. That is a meaningful protection.

Here is the part that should make any owner sit up. Park's lawyers never asked for it. The Court recorded that:

there was no request for an instruction that the Government was required to prove beyond a reasonable doubt that respondent was not without the power or capacity to affect the conditions which founded the charges in the information.

His counsel submitted two requests for jury instructions in total. One of them was simply The fact that John Park is President and Chief Executive Officer of Acme Markets, Inc. does not of itself justify a finding of guilty under Counts I through V of the Information. The impossibility instruction — the one defense the doctrine leaves open — was not among them. The doctrine is named after a man whose defense was available and unrequested.

The Court also showed how it would have analyzed that defense had it been raised, and the reasoning is worth reading if you run a business of any size:

Assuming, arguendo, that it would be objectively impossible for a senior corporate agent to control fully day-to-day conditions in 874 retail outlets, it does not follow that such a corporate agent could not prevent or remedy promptly violations of elementary sanitary conditions in 16 regional warehouses.

In other words: scale is not a blanket excuse. The question gets asked about the specific thing that went wrong, in the specific place it went wrong. A company with hundreds of locations may still be expected to control a handful of warehouses.

The warning letter you already answered becomes evidence against you

This is the most practically important thing on this page, and it is easy to miss.

Park testified that he relied on subordinates he had found to be dependable. The government then introduced the April 1970 FDA letter — the one about the other warehouse, in a different city, eighteen months earlier. Park's lawyers objected. The Supreme Court held the evidence properly admitted, and said exactly what it was for:

its purpose was to demonstrate that respondent was on notice that he could not rely on his system of delegation to subordinates to prevent or correct insanitary conditions at Acme's warehouses, and that he must have been aware of the deficiencies of this system before the Baltimore violations were discovered.

The evidence was therefore relevant since it served to rebut respondent's defense that he had justifiably relied upon subordinates to handle sanitation matters.

So: an earlier FDA letter, about a different facility, on a related problem, was the thing that destroyed the delegation defense. Not because it proved the Baltimore violation. Because it proved he could no longer claim his system was trustworthy.

If your company has received a warning letter and responded to it, that correspondence is not closed in the sense that matters here. It is on the record that you were told. We have a separate page on what happens after a letter response; this is the dimension that page does not cover.

FDA has a written procedure for this, and it is current

None of the above is a historical curiosity. FDA's Regulatory Procedures Manual — the reference manual the agency gives its own staff — devotes a section of Chapter 6 to it, headed Special Procedures and Considerations for Park Doctrine Prosecutions. The copy we fetched is the June 2021 version, version 06, 226 pages, served from an FDA page marked current as of February 1, 2025.

FDA's own statement of the doctrine is the single clearest sentence we found anywhere:

The Park Doctrine, as established by Supreme Court case law, provides that a responsible corporate official can be held liable for a first-time misdemeanor (and possible subsequent felony) under the Act without proof that the corporate official acted with intent or even negligence, and even if such corporate official did not have any actual knowledge of, or participation in, the specific offense.

The manual then tells staff why they might want to use it:

Misdemeanor prosecutions, particularly those against responsible corporate officials, can have a strong deterrent effect on the defendants and other regulated entities.

And it names a consequence that is not a fine and not a prison term:

In some cases, a misdemeanor conviction of an individual may serve as the basis for debarment by FDA.

What FDA tells its staff to weigh

The first consideration restates the Park test, and then adds a sentence that is more honest than the headline version of the doctrine:

consider the individual's position in the company and relationship to the violation, and whether the official had the authority to correct or prevent the violation. … Knowledge of and actual participation in the violation are not a prerequisite to a misdemeanor prosecution but are factors that may be relevant when deciding whether to recommend charging a misdemeanor violation.

So knowledge is not an element, but it is a factor. Not knowing does not stop a prosecution; it may still weigh against bringing one. The manual then lists other factors, which it says are not exhaustive. Among them: whether the violation involves actual or potential harm to the public; whether it is obvious; whether it is widespread; whether it is serious; the quality of the legal and factual support; and Whether the proposed prosecution is a prudent use of agency resources.

One factor on that list deserves its own line, because it connects directly to the Park evidence ruling above:

Whether the violation reflects a pattern of illegal behavior and/or failure to heed prior warnings

Prior warnings appear twice in this story — once in the Supreme Court as admissible evidence that defeats a delegation defense, and once in FDA's internal manual as a factor in whether to recommend charging an individual at all. Those are two different mechanisms pointing at the same piece of paper.

And a step that cuts the other way: it is not a one-person decision

The same section imposes internal friction before any such referral is made, which is worth knowing because it is the opposite of a rubber stamp:

When ORA is considering initiating a referral for a Park Doctrine prosecution, the lead coordinator is required to consult with the appropriate center to ensure that the referral will align with agency priorities and that the center will support the referral and provide expert witnesses or other litigation support when necessary.

A field office cannot simply send one of these forward on its own view of the facts. It has to get a product center to agree that the case fits agency priorities and that the center will supply expert witnesses. That is a real constraint — though, as the manual says of its own factors, it is not a right anybody can enforce.

Do you get a chance to respond before charges? Usually — but not always

The Act provides for a notice and an opportunity to respond before a criminal referral. FDA's manual describes that route:

Criminal referrals for which the agency has provided a notice and opportunity to respond, pursuant to Section 305 of the Act, should follow the procedures described below

And the recommendation behind such a notice includes, in the manual's words, the names and responsibilities of each individual and the charges to be presented in the notice — so individuals are identified by name and by role at that stage.

But there is a set of cases where no such notice is given, and the exceptions are broad:

Those instances in which the agency need not issue a Section 305 notice under the Act are codified in 21 CFR 7.84.

No Section 305 notice is required in cases brought under Title 18 of the United States Code - as opposed to cases brought under the Act - or in cases exempt under 21 CFR 7.84(a)(2) and (3), based on the agency's belief that the notice might result in alteration or destruction of evidence or flight to avoid prosecution.

That first exception swallows a great deal. The peptide prosecutions in this index are very often not Food, Drug, and Cosmetic Act cases at all — they are Title 18 cases, charged as mail fraud or used to support a forfeiture. For those, by FDA's own description of the rule, no Section 305 notice is required.

Why a $50 fine is the dangerous part

Return to § 333(a)(2). A violation committed after a conviction of him under this section has become final is a three-year felony, with no intent requirement. FDA's manual states the consequence plainly:

Once a person has been convicted of a misdemeanor under the Act, any subsequent violation of the Act is a felony, even without proof that the defendant acted with the intent to defraud or mislead.

One precision point, because the two texts are not identical. FDA's manual says Once a person has been convicted. The statute says after a conviction of him under this section has become final. Finality is a legal condition that a conviction does not acquire the moment a jury speaks — it is ordinarily about the exhaustion of appeals. We are not asserting what difference that makes in any particular case; we are noting that the statutory text carries a word the internal manual's summary does not, and that the manual itself disclaims being law.

So the shape of the risk is this. The first conviction is cheap in dollars and may carry no prison at all. What it does is remove the intent requirement from everything that comes afterwards. A business that gets one misdemeanor and keeps operating is a business whose next problem is a felony. For what happens to the sentence at that point, see what turns a misbranding charge into a felony and why most of these cases end in probation.

What does the evidence not show?

Several things, and some of them cut hard against the way this doctrine is usually described.

1. Three justices thought this was wrong, and said the law requires negligence. The decision was not unanimous: Mr. Justice STEWART, with whom Mr. Justice MARSHALL and Mr. Justice POWELL join, dissenting. Their objection was not that officers can never be liable. Justice Stewart accepted the negligence framing explicitly — This is the language of negligence, and I agree with it. — and then said the jury had to be told so:

before a person can be convicted of a criminal violation of this Act, a jury must find … evidence beyond a reasonable doubt that he engaged in wrongful conduct amounting at least to common-law negligence.

His criticism of the instructions actually given is the sharpest line in the case:

The instructions, therefore, expressed nothing more than a tautology. … You must find the defendant guilty if you conclude that he is guilty.

2. The dissent predicted the escalation problem, in 1975. Justice Stewart saw exactly the mechanism described in the section above:

We deal here with a criminal conviction, not a civil forfeiture. It is true that the crime was but a misdemeanor and the penalty in this case light. But under the statute even a first conviction can result in imprisonment for a year, and a subsequent offense is a felony carrying a punishment of up to three years in prison.

So the standardless conviction approved today can serve in another case tomorrow to support a felony conviction and a substantial prison sentence.

Fifty-one years later, the penalty text he was describing is still on the books word for word. The one-year and $1,000 figures, and the three-year and $10,000 figures, read in today's § 333(a)(1) and § 333(a)(2) exactly as the 1975 opinion quoted them from the then-numbered § 333(a) and § 333(b). Only the subsection labels moved.

3. Congress considered requiring intent and the requirement was removed. This is the answer to anybody who argues the absence of an intent element is a drafting accident. The Park Court recorded it in a footnote: We note that in 1948 the Senate passed an amendment to the penalty section to impose criminal liability only for violations committed 'willfully or as a result of gross negligence.' And then: However, the amendment was subsequently stricken in conference. The Senate passed an intent requirement. It did not survive.

4. FDA's manual is not law, and it says so twice. This cuts in the reader's favor and we are stating it as plainly as the agency does. The page the manual sits on says the manual does not create or confer any rights for or on any person and does not operate to bind FDA or the public. The Park Doctrine section repeats it about its own factors: they do not create or confer any rights or benefits for or on any person, and do not operate to bind FDA. So nobody can hold FDA to that list of factors. And the manual immediately removes the comfort you might take from satisfying some of them:

Further, the absence of some factors does not mean that a referral is inappropriate where other factors are evident.

5. Nobody will tell you in advance who counts as a responsible official. Both the courts and the agency have refused to draw that line. FDA puts it this way:

it would be futile to attempt to define or indicate by way of illustration either the categories of persons that may bear a responsible relationship to a violation or the types of conduct that may be viewed as causing or contributing to a violation of the Act.

This means two opposite things at once, and honesty requires both. It means a title does not protect you — there is no list of safe job titles. It also means the government cannot point to a list either, and has to prove the relationship in your particular case, to a jury. The Park trial judge himself told the jury that being president and chief executive does not of itself justify a finding of guilty.

6. The lower courts disagreed, and so did the trial judge who gave the instructions. This was not settled law being routinely applied. The Supreme Court took the case precisely because the circuits had split: We granted certiorari because of an apparent conflict among the Courts of Appeals with respect to the standard of liability of corporate officers under the Federal Food, Drug, and Cosmetic Act. The Court of Appeals below had held that due process required proof of a wrongful act by Park himself, and it was reversed.

More striking, the district judge who delivered the instructions the Supreme Court approved said on the record that he thought the governing case was wrong. Asked to explain what responsible relationship meant, he answered:

Dotterweich and subsequent cases have indicated this really is a jury question. It says it is not even subject to being defined by the Court. As I have indicated to counsel, I am quite candid in stating that I do not agree with the decision; therefore, I am going to stick by it.

A doctrine that the trial judge disliked, the court of appeals rejected, and three justices dissented from is nonetheless the doctrine FDA has written into a current manual. Discomfort with it is old, well documented, and has never changed the outcome.

7. What we could not establish. We did not find, and are not asserting, any figure for how often FDA actually recommends a Park Doctrine prosecution, or how many such prosecutions have been brought in the research-compound field specifically. The manual describes the procedure; it does not report counts. Anyone telling you this is common, or telling you it is a dead letter, is going beyond these documents. We are reporting that the authority exists, that the Supreme Court approved it, and that the agency maintains a current written process for using it.

One document on this page we fetched and will not quote

We looked for a recent research-compound case to sit alongside Park, and fetched a 2026 plea agreement from a federal peptide prosecution — 1,338,163 bytes from the court's own document store. We are not quoting a word of it, and the reason is a rule we apply to ourselves.

Before quoting any archived PDF we classify its text layer from the raw file bytes. That file came back image-covered: 36 embedded images across 10 pages. Text recovered from such a file is a machine's transcription, not the document, and in this case the recovered text proves it — it renders statutory subsection numbers with a lowercase letter l in place of the digit 1, and garbles ordinary words in the caption. A citation built on that is a citation to optical character recognition. So the case does not appear on this page as a source. Our page on searching court filings explains the general problem; this is an instance of it, recorded instead of quietly worked around.

Everything else on this page comes from documents whose text we can read directly: two Supreme Court opinions, two sections of the United States Code, and FDA's manual.

Where this sits in the record

The pages in this index that describe peptide prosecutions almost all describe charges against people — owners, operators, the person who answered the phone. This page is the part of the law that explains how a person becomes the defendant when the thing that went wrong happened somewhere else in the company. It is the mechanism behind a word several of those pages already use. The word misdemeanor appears on ten pages of this index. Why that tier needs no proof that anybody intended anything is the question this page answers.

Two limits on how far this page reaches. It is about the Food, Drug, and Cosmetic Act, and the doctrine is a creature of that Act's penalty structure — it does not transfer to the Title 18 fraud charges that carry much higher ceilings. And it is about criminal liability for individuals, which is a different question from whether a company can be closed, enjoined, or stripped of property; those have their own pages.

Sources

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.